Trials / Completed
CompletedNCT02901951
Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B
Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated 20 to 30 Years Ago With Engerix-B
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the long-term protection against HBV infection in adult subjects, aged 18-40 years vaccinated with three or four doses of Engerix-B 20 to 30 years ago
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Engerix-B | Intramuscular administration of single challenge dose of Engerix-B vaccine in the deltoid region of the non-dominant arm. |
Timeline
- Start date
- 2016-10-11
- Primary completion
- 2017-05-01
- Completion
- 2017-05-01
- First posted
- 2016-09-15
- Last updated
- 2020-01-02
- Results posted
- 2018-08-03
Locations
4 sites across 2 countries: Belgium, Canada
Source: ClinicalTrials.gov record NCT02901951. Inclusion in this directory is not an endorsement.